Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates. However, L1CAM-targeting CAR T cells achieved only limited response against refractory/relapsed neuroblastoma so far. We investigated...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Laura Grunewald, Lena Andersch, Konstantin Helmsauer, Silke Schwiebert, Anika Klaus, Anton G. Henssen, Teresa Straka, Marco Lodrini, Sebastian G. Wicha, Steffen Fuchs, Falk Hertwig, Frank Westermann, Alice Vitali, Carlotta Caramel, Gabriele Büchel, Martin Eilers, Kathy Astrahantseff, Angelika Eggert, Uta E. Höpken, Johannes H. Schulte, Thomas Blankenstein, Kathleen Anders, Annette Künkele
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-02-01
Saila:	Pharmacological Research
Gaiak:	Adoptive T cell therapy Childhood tumor Combination therapy MLN8237 MYCN-driven cancer L1CAM-CAR T cells
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S1043661825000337
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!